Jefferies on BioAge Labs Inc (BIOA): lower dose data reinforces potential BIC, 'layers of momentum build'
Tweet Send to a Friend
Jefferies analyst Roger Song reiterated a Buy rating and $62.00 price target on BioAge Labs Inc (NASDAQ: BIOA)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
